Matthew D Ringel1. 1. Divisions of Endocrinology and Oncology, The Ohio State University College of Medicine and Arthur G. James Comprehensive Cancer Center, Columbus, Ohio, USA. matthew.ringel@osumc.edu
Abstract
BACKGROUND: Metastatic dormancy, or the ability of cancer cells to survive but not progress in metastatic environments, is now recognized to be a common occurrence in cancer. SUMMARY: From a clinical perspective, this phenomenon is common in metastatic well-differentiated thyroid cancer, whereby patients often present with distant metastases that remain stable for years after removal of the primary tumor and subsequent treatment. Experimental data suggest that metastases can develop throughout the life of a cancer and that progression in the distant environment depends on the biology of the cancer cells that metastasize as well as that of the various microenvironments they encounter. A firm understanding of how thyroid cancer cell progression is regulated in different metastatic environments is necessary to devise effective therapies targeting progressive metastatic thyroid cancer. CONCLUSION: In this review, current models of metastatic progression and factors that regulate late-stage metastatic progression that are particularly relevant for thyroid cancer are discussed.
BACKGROUND: Metastatic dormancy, or the ability of cancer cells to survive but not progress in metastatic environments, is now recognized to be a common occurrence in cancer. SUMMARY: From a clinical perspective, this phenomenon is common in metastatic well-differentiated thyroid cancer, whereby patients often present with distant metastases that remain stable for years after removal of the primary tumor and subsequent treatment. Experimental data suggest that metastases can develop throughout the life of a cancer and that progression in the distant environment depends on the biology of the cancer cells that metastasize as well as that of the various microenvironments they encounter. A firm understanding of how thyroid cancer cell progression is regulated in different metastatic environments is necessary to devise effective therapies targeting progressive metastatic thyroid cancer. CONCLUSION: In this review, current models of metastatic progression and factors that regulate late-stage metastatic progression that are particularly relevant for thyroid cancer are discussed.
Authors: Matthew D Ringel; Elena Hardy; Victor J Bernet; Henry B Burch; Frank Schuppert; Kenneth D Burman; Motoyasu Saji Journal: J Clin Endocrinol Metab Date: 2002-05 Impact factor: 5.958
Authors: Vasily Vasko; Allan V Espinosa; William Scouten; Huiling He; Herbert Auer; Sandya Liyanarachchi; Alexander Larin; Victoria Savchenko; Gary L Francis; Albert de la Chapelle; Motoyasu Saji; Matthew D Ringel Journal: Proc Natl Acad Sci U S A Date: 2007-02-12 Impact factor: 11.205
Authors: John M L Ebos; Christina R Lee; William Cruz-Munoz; Georg A Bjarnason; James G Christensen; Robert S Kerbel Journal: Cancer Cell Date: 2009-03-03 Impact factor: 31.743
Authors: Richard T Kloos; Matthew D Ringel; Michael V Knopp; Nathan C Hall; Mark King; Robert Stevens; Jiachao Liang; Paul E Wakely; Vasyl V Vasko; Motoyasu Saji; Jennifer Rittenberry; Lai Wei; Daria Arbogast; Minden Collamore; John J Wright; Michael Grever; Manisha H Shah Journal: J Clin Oncol Date: 2009-03-02 Impact factor: 44.544
Authors: Adam Stenman; L Samuel Hellgren; Kenbugul Jatta; Martin Hysek; Maja Zemmler; Renske Altena; Inga-Lena Nilsson; Robert Bränström; Jan Zedenius; C Christofer Juhlin Journal: Endocr Pathol Date: 2020-03 Impact factor: 3.943
Authors: Chaojie Wang; Motoyasu Saji; Steven E Justiniano; Adlina Mohd Yusof; Xiaoli Zhang; Lianbo Yu; Soledad Fernández; Paul Wakely; Krista La Perle; Hiroshi Nakanishi; Neal Pohlman; Matthew D Ringel Journal: JCI Insight Date: 2017-03-09
Authors: Christine M Chan; Xia Jing; Laura A Pike; Qiong Zhou; Dong-Jun Lim; Sharon B Sams; Gregory S Lund; Vibha Sharma; Bryan R Haugen; Rebecca E Schweppe Journal: Clin Cancer Res Date: 2012-05-14 Impact factor: 12.531